Atriva Therapeutics Secures Us Patent for Mek Inhibitor Zapnometinib (Atr-002)

Atriva Therapeutics, a leader in immunomodulatory and anti-viral therapies, is pleased to announce that it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes claims for the treatment of bacterial infections, the treatment of infections caused by any strain of influenza viruses (including bird flu H5N1), the use of ATR-002 in combination with neuraminidase inhibitors for the treatment of influenza virus infections and the use of ATR-002 for the treatment of co-infections involving influenza viruses and bacteria.

"This pertinent patent grant significantly strengthens Atriva`s patent portfolio and substantially increases its value as we are progressing zapnometinib into Phase 2 clinical development for patients hospitalized with a severe influenza infection”, said Christian Pangratz, Chief Executive Officer of Atriva Therapeutics.

Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. Atriva is continuing the development of zapnometinib in severe viral diseases with epidemic or pandemic potential such as bird flu (H5N1). As a next step, the company is aiming to confirm the promising results from the Phase 2 proof-of-concept study “RESPIRE” – conducted with patients hospitalized with a moderate to severe SARS-CoV-2 infection – in a Phase 2 clinical trial with patients hospitalized with a severe influenza infection, potentially also caused by bird flu H5N1.

The RESPIRE trial was funded by Atriva Therapeutics, the German Federal Ministry of Education and Research and co-funded by the European Investment Bank.